RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Hua Medicine of Shanghai has started a US Phase I trial of its lead drug, dorzagliatin, a first-in-class oral glucokinase activator (GKA), in patients with type 2 diabetes not controlled by metformin, a DPP-4 inhibitor or a SGLT2 inhibitor. The trial will test the PK/PD of dorzagliatin together with empagliflozin, the Boehringer Ingelheim SGLT2 inhibitor known as Jardiance. The trial’s endpoints are pharmacokinetic interaction between the two molecules, plus safety and tolerability of the combination.
Source: China Biotoday
